Table 4.

MCS; the 3 workshop cases

	Case 230	Case 241	Case 326
Gender, age	Male, 61 years	Male, 65 years	Male, 38 years
History	AML with trisomy 8 and mutations FLT3 S451F, IDH2 R140Q, and SRSF2 P95H, for which clinical and cytogenetic remission achieved after HSCT	Urothelial carcinoma of the renal pelvis treated by nephrotomy	Refractory T-cell lympoblastic leukemia/lymphoma (TCR-gamma delta+) treated with post chemotherapy and allogeneic HSCT
Organs involved	Left inferior pubic ramus	Multiple (lytic) bone lesions	Small bowel, ascites, liver, and omental nodules
IHC	Positive: CD117 Weakly positive: tryptase Negative: CD2, CD3, CD25, CD34	Positive: CD30, tryptase, CD117, CD25 +/– Negative: CD20, CD79a, CD3, CD5, ALK, CD34, MPO, Glycophorin, FVIII	Positive: tryptase, CD68 (KP-1), CD123, CD117, CD2, and CD25 Negative: TdT
Flow	Positive: CD45, CD33, CD117, CD13 Variable: CD38, CD64, Dim: CD7, CD4 (negative to partially dim) Negative: CD2, CD14, CD15, CD16, CD25, CD34, CD36, CD56, CD123, HLA-DR, CD11b (predominantly negative)	Not available	Positive: CD117, CD123, CD25, CD2, CD33 Dim: CD45, CD13 Negative: CD34, MPO, TdT
Mutations	Imatinib-sensitive mutation KIT Y503_ F504insAY in exon 9, along with IDH2 R140Q and SRSF2 P95H mutations identical to the initial AML	No KIT D816V mutation	Complex karyotype: 78-89, XXXX, del(3) (p12p26), add(9)(p23), del(9)(p12-24), add(21) (p11.2)inc[cp 18] No KIT mutation
Outcome	Treated with irradiation and daily imatinib for 5.5 months, on which he achieved complete remission.	Treated with midostaurine without effect, then dasatinib with 5-azacytidine; survival: 6 months	Palliative therapy Survival: 1 month